Leveraging Knowledge From Cytotoxic ADCs & Other Modalities to Assess Pharmacology Profiles of Next- Generation ADCs
- Leveraging systems pharmacology modeling to understand ADC behavior and MoA
- Combining knowledge from novel payloads with classical cytotoxic ADCs to impact future ADC constructs
- Utilizing pharmacology characterization to assist with translation and first-in-human dosing strategy